Ascentage Pharma Group International (Incorporated in the Cayman Islands with limited liability)
Climate Impact & Sustainability Data (2019)
Reporting Period: 2019
Environmental Metrics
Total Carbon Emissions:907.28 ton of CO2 equivalent
Scope 2 Emissions:900.91 ton of CO2 equivalent
Total Energy Consumption:1,282,133.47 kWh
Water Consumption:4,360.80 m3
Waste Generated:4,360.80 tons
ESG Focus Areas
- Environmental responsibility
- Labor responsibility
- Operational responsibility
- Corporate governance responsibility
Environmental Achievements
- Reduced emissions of pollutants to atmosphere, soil and waters by constantly improving process and implementing management and operation responsibility system
- Implemented waste management system to regulate the management of waste collection, classification, storage, transfer and disposal
Social Achievements
- Staff retention rate exceeded 90%
- Donated RMB500,000 to Wuhan Union Hospital and Wuhan Tongji Hospital for purchasing urgently needed medical supplies to combat the epidemic
- Organized procurement of supplies, spending a total amount of RMB500,000 to purchase urgently needed medical supplies from the United States, which were delivered to various hospitals in Wuhan
- Encouraged all employees to make voluntary donations to purchase and donate 400 medical disposable protective clothing to Peking University People’s Hospital
Governance Achievements
- Successfully listed on the Stock Exchange
- Implemented comprehensive risk management policies at the business operation level to systematically manage various ESG risks
- Established an Anti-Corruption Policy to safeguard against corruption; set up an internal reporting channel that is open and available for employees to report any suspected non-compliance
Climate Goals & Targets
Environmental Challenges
- Potential safety hazards during the production or quality inspection of drugs
- Potential safety hazards discovered in the complaint management procedures
- Notices on defects from material suppliers
- Regulatory authorities’ requirements on drug recalls and inquiries of drug quality by other authoritative institutions
Mitigation Strategies
- Formulated and implemented a series of policies to ensure the safety of clinical trials
- Strictly monitor the possibility for adverse events or quality issues, and follow up and adjust the trials in a timely manner
- Established procedures for receiving and handling complaints in relation to drugs in clinical trials
- Initiate the drug recall procedures and promptly recall products in accordance with the Clinical Trial Drug Recall Procedures
Supply Chain Management
Supplier Audits: approximately 300 suppliers
Responsible Procurement
- Procurement and Supply Management Regulations
- GMP Materials Procurement Management
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: ESG Guide as contained in Appendix 27 to The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
Awards & Recognition
- Innovative Team in Jiangsu Province
- The Most Innovative Pharmaceutical Enterprise in the Asia-Pacific Region
- Suzhou Biomedical Industrial Park EHS Best Practice Enterprise
- Celebrating 70th Birthday of the Country and Building a New Era of Prosperity, Outstanding Enterprise in the Pharmaceutical Industry
- New Wisdom Forum • 2019 Annual Value Pioneer Chart in Pharmaceutical Industry — Most Valuable Growing Enterprise in Pharmaceutical Industry